Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Summary

Gilead Sciences (GILD) reported strong financial results for Q4 and full year 2024. Total revenue increased 6% to $28.8 billion for the full year, driven by higher sales in HIV, Oncology, and Liver Disease. Product sales excluding Veklury grew 8% to $26.8 billion.

Key highlights include Biktarvy sales increasing 13% to $13.4 billion, HIV product sales rising 8% to $19.6 billion, and Oncology sales growing 12% to $3.3 billion for full year 2024. The company's cash position strengthened to $10.0 billion by year-end.

For 2025 guidance, Gilead expects product sales between $28.2-28.6 billion, with non-Veklury sales of $26.8-27.2 billion. The company projects diluted EPS of $5.95-6.35 and non-GAAP diluted EPS of $7.70-8.10.

Positive

• Revenue increased 6% to $28.8 billion in 2024
• Product sales excluding Veklury grew 8% to $26.8 billion
• Biktarvy sales increased 13% to $13.4 billion
• HIV product sales rose 8% to $19.6 billion
• Cash position improved to $10.0 billion from $8.4 billion YoY
• Generated $3.0 billion in operating cash flow in Q4

Negative

• Veklury sales decreased 18% to $1.8 billion
• Full year diluted EPS decreased to $0.38 from $4.50 in 2023
• Non-GAAP diluted EPS declined to $4.62 from $6.72 in 2023
• Recorded $4.2 billion IPR&D impairment charge related to Immunomedics assets

Insights

Financial Analyst

Gilead's Q4 and full-year 2024 results reveal a company executing effectively on multiple fronts while positioning for future growth. The 8% year-over-year growth in base business to $26.8 billion demonstrates strong commercial execution, particularly in the face of declining COVID-19 related revenues.

The HIV franchise continues to be the primary growth driver, with Biktarvy's 13% full-year growth to $13.4 billion showcasing its market dominance. The upcoming potential launch of lenacapavir for HIV PrEP in Summer 2025 represents a significant opportunity to expand the company's preventive care portfolio and capture additional market share in the growing PrEP market.

Operational efficiency improvements are evident in the expanded product gross margin of 79.0% in Q4, up from 70.4% in the same period last year. The strong cash position of $10 billion and robust operating cash flow of $3 billion in Q4 provide ample flexibility for strategic investments and shareholder returns.

The oncology portfolio's 12% growth to $3.3 billion for the full year, driven by Trodelvy's 24% growth, indicates successful diversification beyond the core HIV business. The recently granted Breakthrough Therapy Designation for Trodelvy in ES-SCLC could further accelerate this momentum.

Looking ahead to 2025, the guidance of $28.2-28.6 billion in product sales reflects management's confidence in sustained growth, despite expected continued decline in Veklury sales. The company's strategic focus on operational efficiency, portfolio diversification, and pipeline advancement positions it well for long-term value creation.

Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024

Biktarvy Sales Increased 13% Year-Over-Year to $13.4 billion for Full Year 2024

Oncology Sales Increased 12% Year-Over-Year to $3.3 billion for Full Year 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

“Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year for the fourth quarter,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PrEP in Summer 2025, with its unique opportunity to extend the reach of HIV prevention. This potential in HIV, along with our strong and diverse portfolio, and improved operational efficiencies, positions Gilead to deliver increasing patient impact and compelling shareholder returns in the years ahead.”

Fourth Quarter 2024 Financial Results

• Total fourth quarter 2024 revenue increased 6% to $7.6 billion compared to the same period in 2023, primarily due to higher sales in HIV, as well as in Oncology and Liver Disease, partially offset by lower sales of Veklury® (remdesivir).
• Diluted Earnings Per Share (“EPS”) increased to $1.42 in the fourth quarter 2024 compared to $1.14 in the same period in 2023, primarily driven by lower costs of goods sold, higher product sales and lower acquired in-process research and development ("IPR&D") expenses, partially offset by higher operating expenses as well as unrealized losses on equity investments in 2024 compared to gains in 2023.
• Non-GAAP diluted EPS increased to $1.90 in the fourth quarter 2024 compared to $1.72 in the same period in 2023. The increase was primarily driven by higher product sales and lower acquired IPR&D expenses, partially offset by higher operating expenses.
• As of December 31, 2024, Gilead had $10.0 billion of cash, cash equivalents and marketable debt securities compared to $8.4 billion as of December 31, 2023.
• During the fourth quarter 2024, Gilead generated $3.0 billion in operating cash flow.
• During the fourth quarter 2024, Gilead issued senior unsecured notes in an aggregate principal amount of $3.5 billion, paid cash dividends of $973 million and utilized $350 million to repurchase common stock.

Fourth Quarter 2024 Product Sales

Total fourth quarter 2024 product sales increased 7% to $7.5 billion compared to the same period in 2023. Total product sales excluding Veklury increased 13% to $7.2 billion compared to the same period in 2023, primarily due to higher sales in HIV, as well as in Oncology and Liver Disease.

HIV product sales increased 16% to $5.5 billion in the fourth quarter 2024 compared to the same period in 2023, primarily driven by higher demand, higher average realized price and favorable inventory dynamics.

• Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 21% to $3.8 billion in the fourth quarter 2024 compared to the same period in 2023, primarily driven by higher demand, favorable inventory dynamics and higher average realized price.
• Descovy® (FTC 200mg/TAF 25mg) sales increased 21% to $616 million in the fourth quarter 2024 compared to the same period in 2023, primarily driven by higher demand, higher average realized price and favorable inventory dynamics.

The Liver Disease portfolio sales increased 4% to $719 million in the fourth quarter 2024 compared to the same period in 2023. This was primarily driven by the launch of Livdelzi® (seladelpar) in primary biliary cholangitis (“PBC”), and increased demand in products for chronic hepatitis B virus (“HBV”) and chronic hepatitis delta virus (“HDV”), partially offset by lower demand and average realized price in products for chronic hepatitis C virus (“HCV”).

Veklury sales decreased 53% to $337 million in the fourth quarter 2024 compared to the same period in 2023, primarily driven by lower rates of COVID-19 related hospitalizations, particularly in the United States.

Cell Therapy product sales increased 5% to $488 million in the fourth quarter 2024 compared to the same period in 2023.

• Yescarta® (axicabtagene ciloleucel) sales increased 6% to $390 million in the fourth quarter 2024 compared to the same period in 2023, primarily driven by higher average realized price and increased demand outside of the United States, partially offset by lower demand in the United States.
• Tecartus® (brexucabtagene autoleucel) sales of $98 million in the fourth quarter 2024 were flat compared to the same period in 2023, reflecting increased demand outside of the United States, offset by lower demand in the United States.

Trodelvy® (sacituzumab govitecan-hziy) sales increased 19% to $355 million in the fourth quarter 2024 compared to the same period in 2023, primarily driven by increased demand in all regions, as well as higher average realized price.

Fourth Quarter 2024 Product Gross Margin, Operating Expenses and Tax

• Product gross margin was 79.0% in the fourth quarter 2024 compared to 70.4% in the same period in 2023, primarily driven by prior year restructuring expenses related to changes in our manufacturing strategy. Non-GAAP product gross margin was 86.7% in the fourth quarter 2024 compared to 86.1% in the same period in 2023.
• Research and development (“R&D”) expenses were $1.6 billion in the fourth quarter 2024 compared to $1.4 billion in the same period in 2023, primarily due to incremental investments and clinical activities across our portfolio and the impact of a prior year valuation adjustment to the MYR-related contingent consideration that did not repeat. Non-GAAP R&D expenses were $1.6 billion in the fourth quarter 2024 compared to $1.5 billion in the same period in 2023, primarily due to incremental investments and clinical activities across our portfolio.
• Acquired IPR&D expenses were $(11) million in the fourth quarter 2024, reflecting expenses related to the Terray Therapeutics, Inc. (“Terray”) and Tubulis GmbH (“Tubulis”) collaborations, offset by a favorable adjustment related to the CymaBay Therapeutics, Inc. (“CymaBay”) acquisition.
• Selling, general and administrative (“SG&A”) and non-GAAP SG&A expenses were $1.9 billion in the fourth quarter 2024 compared to $1.6 billion in the same period in 2023, primarily driven by a litigation accrual and higher sales and marketing spending, including launch preparation activities for lenacapavir for the investigational use of HIV pre-exposure prophylaxis (“PrEP”) as well as for Livdelzi.
• The effective tax rate (“ETR”) was 17.8% in the fourth quarter 2024 compared to 14.3% in the same period in 2023, primarily due to prior year settlements with tax authorities and non-taxable unrealized gains and losses on equity investments. Non-GAAP ETR was 19.2% in the fourth quarter 2024 compared to 17.1% in the same period in 2023, primarily due to prior year settlements with tax authorities.

Full Year 2024 Financial Results

• Total full year 2024 revenue increased 6% to $28.8 billion compared to 2023, primarily due to higher sales in HIV, Oncology and Liver Disease, partially offset by lower sales of Veklury.
• Diluted EPS decreased to $0.38 in the full year 2024 compared to $4.50 in 2023. The decrease was primarily driven by a pre-tax IPR&D impairment charge of $4.2 billion, or $2.49 per share net of tax impact, related to assets acquired by Gilead from Immunomedics, Inc. (“Immunomedics”) in 2020, and acquired IPR&D charges of $3.9 billion, or $3.14 per share, in the first quarter 2024 related to the acquisition of CymaBay, partially offset by higher product sales.
• Non-GAAP diluted EPS decreased to $4.62 in the full year 2024 compared to $6.72 in 2023. This was primarily driven by higher acquired IPR&D expenses related to the CymaBay acquisition and higher income tax expense, partially offset by higher product sales.

Full Year 2024 Product Sales

Total full year 2024 product sales increased 6% to $28.6 billion compared to 2023. Total product sales excluding Veklury increased 8% to $26.8 billion in the full year 2024 compared to 2023, primarily driven by higher sales in HIV, Oncology and Liver Disease.

HIV product sales increased 8% to $19.6 billion in the full year 2024 compared to 2023, primarily driven by higher demand, as well as the impact of higher average realized price.

• Biktarvy sales increased 13% to $13.4 billion in the full year 2024 compared to 2023, primarily driven by higher demand.
• Descovy sales increased 6% to $2.1 billion in the full year 2024 compared to 2023, primarily driven by higher demand, partially offset by lower average realized price.

The Liver Disease portfolio sales increased 9% to $3.0 billion in the full year 2024 compared to 2023. The increase was primarily due to higher demand across all liver diseases.

Veklury sales decreased 18% to $1.8 billion in the full year 2024 compared to 2023, primarily driven by lower rates of COVID-19 related hospitalizations.

Cell Therapy product sales increased 6% to $2.0 billion in the full year 2024 compared to 2023.

• Yescarta sales increased 5% to $1.6 billion in the full year 2024 compared to 2023, primarily driven by increased demand outside of the United States and higher average realized price, partially offset by lower demand in the United States.
• Tecartus sales increased 9% to $403 million in the full year 2024 compared to 2023, primarily driven by increased demand outside of the United States, partially offset by lower demand in the United States.

Trodelvy sales increased 24% to $1.3 billion in the full year 2024 compared to 2023, primarily driven by increased demand in all regions.

Full Year 2024 Product Gross Margin, Operating Expenses and Tax

• Product gross margin was 78.2% in the full year 2024 compared to 75.9% in 2023, primarily driven by prior year restructuring expenses related to changes in our manufacturing strategy. Non-GAAP product gross margin was 86.2% in the full year 2024 compared to 86.3% in 2023.
• R&D expenses were $5.9 billion in the full year 2024 compared to $5.7 billion in 2023, primarily driven by restructuring costs and integration expenses related to the CymaBay acquisition. Non-GAAP R&D expenses of $5.7 billion in the full year 2024 were flat compared to 2023.
• Acquired IPR&D expenses were $4.7 billion in the full year 2024 compared to $1.2 billion in 2023, primarily reflecting the acquisition of CymaBay.
• SG&A expenses of $6.1 billion in the full year 2024 were flat compared to 2023, reflecting higher sales and marketing spending, including launch preparation activities for lenacapavir for the investigational use of HIV PrEP as well as for Livdelzi, integration costs related to the acquisition of CymaBay, and restructuring expenses, offset by lower expenses related to legal matters. Non-GAAP SG&A expenses were $5.9 billion in the full year 2024 compared to $6.1 billion in 2023, primarily driven by lower expenses related to legal matters, partially offset by higher sales and marketing spending, including launch preparation activities for lenacapavir for the investigational use of HIV PrEP as well as for Livdelzi.
• The ETR was 30.5% in the full year 2024 compared to 18.2% in 2023, primarily driven by the non-deductible acquired IPR&D charge for CymaBay and prior year decrease in tax reserves that did not repeat, partially offset by the tax impact of a legal entity restructuring and Immunomedics IPR&D impairment expense, as well as current year settlements with tax authorities and remeasurement of certain deferred tax liabilities. Non-GAAP ETR was 25.9% in the full year 2024 compared to 15.2% in 2023, primarily due to the non-deductible acquired IPR&D charge for CymaBay and a prior year decrease in tax reserves that did not repeat, partially offset by current year settlements with tax authorities.

Guidance and Outlook

For the full-year 2025, Gilead expects:

(in millions, except per share amounts)		February 11, 2025 Guidance
		Low End			High End
Product sales		$	28,200		$	28,600
Product sales excluding Veklury		$	26,800		$	27,200
Veklury		$	1,400		$	1,400
Diluted EPS		$	5.95		$	6.35
Non-GAAP diluted EPS		$	7.70		$	8.10

Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2025 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below.

Key Updates Since Our Last Quarterly Release

Virology

• Presented new HIV data at the International Congress on Drug Therapy in HIV Infection (“HIV Glasgow 2024”). This included full results from the Phase 3 PURPOSE 2 trial evaluating investigational twice-yearly lenacapavir for HIV prevention among cisgender men and gender-diverse people, with data published in the New England Journal of Medicine.
• Additionally at HIV Glasgow 2024, presented new HIV treatment research data from Biktarvy, as well as for investigational regimens with once-daily, once-weekly and twice-yearly dosing frequencies.
• Completed the New Drug Application submissions to U.S. Food and Drug Administration (“FDA”), as well as a marketing authorization application and an EU-Medicines for All application to the European Medicines Agency (“EMA”), for twice-yearly lenacapavir for HIV prevention.
• Lenacapavir named by Science Magazine as its 2024 “Breakthrough of the Year,” based in part on the PURPOSE 1 and PURPOSE 2 trial results.

Oncology

• Our partner, Arcellx, Inc. (“Arcellx”), presented new data evaluating investigational anitocabtagene autoleucel (“anito-cel”) in relapsed or refractory (“R/R”) multiple myeloma at the American Society of Hematology 2024 Annual Meeting (“ASH 2024”). This included preliminary data from the registrational Phase 2 iMMagine-1 trial, as well as updated Phase 1 data.
• Presented new data at ASH 2024 including long-term follow-up of Yescarta in R/R non-Hodgkin’s lymphoma and Tecartus in R/R mantle cell lymphoma, as well as real world data for Yescarta in R/R large B-cell lymphoma and Tecartus in B-cell precursor adult acute lymphoblastic leukemia.
• Granted Breakthrough Therapy Designation by FDA to Trodelvy for the treatment of adult patients with extensive-stage small cell lung cancer (“ES-SCLC”) whose disease has progressed on or after platinum-based chemotherapy. The use of Trodelvy in ES-SCLC is investigational.
• Entered into a single-asset focused collaboration, license, and option agreement with Tubulis to develop an antibody-drug conjugate candidate for a solid tumor target using Tubulis’ Tubutecan and Alco5 platforms.

Inflammation

• Received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use recommending seladelpar for the treatment of PBC in combination with ursodeoxycholic acid (“UDCA”) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
• Received marketing authorization from the Medicines and Healthcare products Regulatory Agency in the UK for seladelpar for treatment of PBC, including pruritus, in adults in combination with UDCA who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
• Presented new data evaluating seladelpar in PBC at the American Association for the Study of Liver Diseases’ The Liver Meeting. This included longer-term follow-up data from the ASSURE trial, as well as additional analyses from the RESPONSE trial.
• Announced a strategic partnership to develop and commercialize the pre-clinical oral STAT6 program of LEO Pharma A/S (“LEO Pharma”) for the potential treatment of inflammatory diseases.

Corporate

• Appointed Dietmar Berger, MD, PhD, as Chief Medical Officer effective January 2025.
• Entered into a strategic research collaboration with Terray to discover and develop novel, small molecule therapies across multiple targets using Terray’s artificial intelligence tNOVA platform.
• Reached a final settlement agreement with the U.S. Department of Justice and the U.S. Department of Health and Human Services on patents that the government alleged covered Truvada® (FTC 200mg/tenofovir disoproxil fumarate (“TDF”) 300mg) and Descovy for HIV PrEP.
• Issued $3.5 billion aggregate principal amount of senior unsecured notes in a registered offering.
• The Board declared a quarterly dividend of $0.79 per share of common stock for the first quarter of 2025. The dividend is payable on March 28, 2025, to stockholders of record at the close of business on March 14, 2025. Future dividends will be subject to Board approval.

Certain amounts and percentages in this press release may not sum or recalculate due to rounding.

Conference Call

At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.

Non-GAAP Financial Information

The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with such exclusions as well as changes in tax-related laws and guidelines, transfers of intangible assets between certain legal entities, and legal entity restructurings. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its full year 2025 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues; Gilead’s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangements with Arcellx, LEO Pharma, Terray and Tubulis; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Biktarvy, Tecartus, Trodelvy, Yescarta, anito-cel, lenacapavir and seladelpar (such as the ASSURE, iMMagine-1, PURPOSE 1 and 2, and RESPONSE studies), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines, including for lenacapavir for HIV PrEP and seladelpar for PBC; Gilead’s ability to receive or maintain regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies and may therefore be reluctant to prescribe the products, including Livdelzi; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended December 31, 2024 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE^TM, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LIVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA® , TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
		Three Months Ended								Twelve Months Ended
		December 31,								December 31,
(in millions, except per share amounts)			2024				2023				2024				2023
Revenues:
Product sales		$	7,536			$	7,070			$	28,610			$	26,934
Royalty, contract and other revenues			33				45				144				182
Total revenues			7,569				7,115				28,754				27,116
Costs and expenses:
Cost of goods sold			1,581				2,090				6,251				6,498
Research and development expenses			1,641				1,408				5,907				5,718
Acquired in-process research and development expenses			(11	)			347				4,663				1,155
In-process research and development impairments			—				50				4,180				50
Selling, general and administrative expenses			1,906				1,608				6,091				6,090
Total costs and expenses			5,118				5,503				27,092				19,511
Operating income			2,451				1,612				1,662				7,605
Interest expense			248				252				977				944
Other (income) expense, net			35				(293	)			(6	)			(198	)
Income before income taxes			2,168				1,653				690				6,859
Income tax expense			385				236				211				1,247
Net income			1,783				1,417				480				5,613
Net loss attributable to noncontrolling interest			—				(12	)			—				(52	)
Net income attributable to Gilead		$	1,783			$	1,429			$	480			$	5,665
Basic earnings per share attributable to Gilead		$	1.43			$	1.15			$	0.38			$	4.54
Shares used in basic earnings per share attributable to Gilead calculation			1,248				1,248				1,247				1,248
Diluted earnings per share attributable to Gilead		$	1.42			$	1.14			$	0.38			$	4.50
Shares used in diluted earnings per share attributable to Gilead calculation			1,259				1,256				1,255				1,258
Supplemental Information:
Cash dividends declared per share		$	0.77			$	0.75			$	3.08			$	3.00
Product gross margin			79.0	%			70.4	%			78.2	%			75.9	%
Research and development expenses as a % of revenues			21.7	%			19.8	%			20.5	%			21.1	%
Selling, general and administrative expenses as a % of revenues			25.2	%			22.6	%			21.2	%			22.5	%
Operating margin			32.4	%			22.7	%			5.8	%			28.0	%
Effective tax rate			17.8	%			14.3	%			30.5	%			18.2	%

GILEAD SCIENCES, INC. TOTAL REVENUE SUMMARY (unaudited)
		Three Months Ended								Twelve Months Ended
		December 31,								December 31,
(in millions, except percentages)		2024			2023			Change		2024			2023			Change
Product sales:
HIV		$	5,452		$	4,693		16%		$	19,612		$	18,175		8%
Liver Disease			719			691		4%			3,021			2,784		9%
Oncology			843			765		10%			3,289			2,932		12%
Other			184			201		(8)%			889			859		3%
Total product sales excluding Veklury			7,198			6,350		13%			26,811			24,750		8%
Veklury			337			720		(53)%			1,799			2,184		(18)%
Total product sales			7,536			7,070		7%			28,610			26,934		6%
Royalty, contract and other revenues			33			45		(26)%			144			182		(21)%
Total revenues		$	7,569		$	7,115		6%		$	28,754		$	27,116		6%

GILEAD SCIENCES, INC. NON-GAAP FINANCIAL INFORMATION(1) (unaudited)
		Three Months Ended										Twelve Months Ended
		December 31,										December 31,
(in millions, except percentages)			2024				2023			Change			2024				2023			Change
Non-GAAP:
Cost of goods sold		$	1,002			$	980			2%		$	3,936			$	3,697			6%
Research and development expenses		$	1,612			$	1,452			11%		$	5,732			$	5,720			—%
Acquired IPR&D expenses(2)		$	(11	)		$	347			NM		$	4,663			$	1,155			NM
Selling, general and administrative expenses		$	1,852			$	1,597			16%		$	5,903			$	6,060			(3)%
Other (income) expense, net		$	(91	)		$	(104	)		(13)%		$	(279	)		$	(365	)		(24)%
Diluted EPS		$	1.90			$	1.72			10%		$	4.62			$	6.72			(31)%
Shares used in non-GAAP diluted earnings per share attributable to Gilead calculation			1,259				1,256			—%			1,255				1,258			—%
Product gross margin			86.7	%			86.1	%		56 bps			86.2	%			86.3	%		-3 bps
Research and development expenses as a % of revenues			21.3	%			20.4	%		89 bps			19.9	%			21.1	%		-116 bps
Selling, general and administrative expenses as a % of revenues			24.5	%			22.4	%		203 bps			20.5	%			22.3	%		-182 bps
Operating margin			41.1	%			38.5	%		265 bps			29.6	%			38.7	%		-903 bps
Effective tax rate			19.2	%			17.1	%		210 bps			25.9	%			15.2	%		1075 bps

________________________________
NM - Not Meaningful
(1)		Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below.
(2)		Equal to GAAP financial information.

GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited)
		Three Months Ended								Twelve Months Ended
		December 31,								December 31,
(in millions, except percentages and per share amounts)			2024				2023				2024				2023
Cost of goods sold reconciliation:
GAAP cost of goods sold		$	1,581			$	2,090			$	6,251			$	6,498
Acquisition-related – amortization(1)			(579	)			(580	)			(2,316	)			(2,271	)
Restructuring			—				(479	)			—				(479	)
Other(2)			—				(51	)			—				(51	)
Non-GAAP cost of goods sold		$	1,002			$	980			$	3,936			$	3,697
Product gross margin reconciliation:
GAAP product gross margin			79.0	%			70.4	%			78.2	%			75.9	%
Acquisition-related – amortization(1)			7.7	%			8.2	%			8.1	%			8.4	%
Restructuring			—	%			6.8	%			(—	)%			1.8	%
Other(2)			—	%			0.7	%			—	%			0.2	%
Non-GAAP product gross margin			86.7	%			86.1	%			86.2	%			86.3	%
Research and development expenses reconciliation:
GAAP research and development expenses		$	1,641			$	1,408			$	5,907			$	5,718
Acquisition-related – other costs(3)			—				59				(78	)			22
Restructuring			(30	)			(15	)			(98	)			(20	)
Non-GAAP research and development expenses		$	1,612			$	1,452			$	5,732			$	5,720
IPR&D impairment reconciliation:
GAAP IPR&D impairment		$	—			$	50			$	4,180			$	50
IPR&D impairment			—				(50	)			(4,180	)			(50	)
Non-GAAP IPR&D impairment		$	—			$	—			$	—			$	—
Selling, general and administrative expenses reconciliation:
GAAP selling, general and administrative expenses		$	1,906			$	1,608			$	6,091			$	6,090
Acquisition-related – other costs(3)			(8	)			—				(97	)			(2	)
Restructuring			(46	)			(11	)			(91	)			(28	)
Non-GAAP selling, general and administrative expenses		$	1,852			$	1,597			$	5,903			$	6,060
Operating income reconciliation:
GAAP operating income		$	2,451			$	1,612			$	1,662			$	7,605
Acquisition-related – amortization(1)			579				580				2,316				2,271
Acquisition-related – other costs(3)			8				(59	)			174				(20	)
Restructuring			76				505				188				527
IPR&D impairment			—				50				4,180				50
Other(2)			—				51				—				51
Non-GAAP operating income		$	3,114			$	2,739			$	8,520			$	10,484
Operating margin reconciliation:
GAAP operating margin			32.4	%			22.7	%			5.8	%			28.0	%
Acquisition-related – amortization(1)			7.6	%			8.1	%			8.1	%			8.4	%
Acquisition-related – other costs(3)			0.1	%			(0.8	)%			0.6	%			(0.1	)%
Restructuring			1.0	%			7.1	%			0.7	%			1.9	%
IPR&D impairment			—	%			0.7	%			14.5	%			0.2	%
Other(2)			—	%			0.7	%			—	%			0.2	%
Non-GAAP operating margin			41.1	%			38.5	%			29.6	%			38.7	%
Other (income) expense, net reconciliation:
GAAP other (income) expense, net		$	35			$	(293	)		$	(6	)		$	(198	)
(Loss) gain from equity securities, net			(126	)			189				(274	)			(167	)
Non-GAAP other (income) expense, net		$	(91	)		$	(104	)		$	(279	)		$	(365	)

GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited)
		Three Months Ended								Twelve Months Ended
		December 31,								December 31,
(in millions, except percentages and per share amounts)			2024				2023				2024				2023
Income before income taxes reconciliation:
GAAP income before income taxes		$	2,168			$	1,653			$	690			$	6,859
Acquisition-related – amortization(1)			579				580				2,316				2,271
Acquisition-related – other costs(3)			8				(59	)			174				(20	)
Restructuring			76				505				188				527
IPR&D impairment			—				50				4,180				50
Loss (gain) from equity securities, net			126				(189	)			274				167
Other(2)			—				51				—				51
Non-GAAP income before income taxes		$	2,956			$	2,591			$	7,822			$	9,905
Income tax expense reconciliation:
GAAP income tax (benefit) expense		$	385			$	236			$	211			$	1,247
Income tax effect of non-GAAP adjustments:
Acquisition-related – amortization(1)			121				119				484				466
Acquisition-related – other costs(3)			2				1				41				9
Restructuring			16				90				37				95
IPR&D impairment			—				15				1,051				15
Loss (gain) from equity securities, net			13				(18	)			(39	)			(14	)
Discrete and related tax charges(4)			29				(12	)			243				(326	)
Other(2)			—				11				—				11
Non-GAAP income tax expense		$	566			$	442			$	2,028			$	1,503
Effective tax rate reconciliation:
GAAP effective tax rate			17.8	%			14.3	%			30.5	%			18.2	%
Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(4)			1.4	%			2.8	%			(4.6	)%			(3.0	)%
Non-GAAP effective tax rate			19.2	%			17.1	%			25.9	%			15.2	%
Net income attributable to Gilead reconciliation:
GAAP net income attributable to Gilead		$	1,783			$	1,429			$	480			$	5,665
Acquisition-related – amortization(1)			458				460				1,832				1,805
Acquisition-related – other costs(3)			6				(59	)			134				(29	)
Restructuring			59				414				151				431
IPR&D impairment			—				35				3,129				35
Loss (gain) from equity securities, net			113				(171	)			313				180
Discrete and related tax charges(4)			(29	)			12				(243	)			326
Other(2)			—				40				—				40
Non-GAAP net income attributable to Gilead		$	2,390			$	2,161			$	5,795			$	8,454
Diluted earnings per share reconciliation:
GAAP diluted earnings per share		$	1.42			$	1.14			$	0.38			$	4.50
Acquisition-related – amortization(1)			0.36				0.37				1.46				1.43
Acquisition-related – other costs(3)			—				(0.05	)			0.11				(0.02	)
Restructuring			0.05				0.33				0.12				0.34
IPR&D impairment			—				0.03				2.49				0.03
Loss (gain) from equity securities, net			0.09				(0.14	)			0.25				0.14
Discrete and related tax charges(4)			(0.02	)			0.01				(0.19	)			0.26
Other(2)			—				0.03				—				0.03
Non-GAAP diluted earnings per share		$	1.90			$	1.72			$	4.62			$	6.72
		Three Months Ended								Twelve Months Ended
		December 31,								December 31,
(in millions, except percentages and per share amounts)			2024				2023				2024				2023
Non-GAAP adjustment summary:
Cost of goods sold adjustments		$	579			$	1,110			$	2,315			$	2,801
Research and development expenses adjustments			29				(44	)			176				(2	)
IPR&D impairment adjustments			—				50				4,180				50
Selling, general and administrative expenses adjustments			54				11				188				30
Total non-GAAP adjustments to costs and expenses			663				1,127				6,858				2,879
Other (income) expense, net, adjustments			126				(189	)			274				167
Total non-GAAP adjustments before income taxes			789				938				7,132				3,046
Income tax effect of non-GAAP adjustments above			(152	)			(218	)			(1,574	)			(583	)
Discrete and related tax charges(4)			(29	)			12				(243	)			326
Total non-GAAP adjustments to net income attributable to Gilead		$	607			$	732			$	5,315			$	2,789

________________________________
(1)		Relates to amortization of acquired intangibles.
(2)		Relates to a write-off of an intangible asset related to the restructuring of our collaboration with Galapagos NV during the fourth quarter of 2023.
(3)		Adjustments include integration expenses, contingent consideration fair value adjustments and other expenses associated with Gilead’s recent acquisitions.
(4)		Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and in-process research and development, transfers of intangible assets from a foreign subsidiary to Ireland and the United States, and legal entity restructurings.

GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP 2025 FULL YEAR GUIDANCE(1) (unaudited)
(in millions, except percentages and per share amounts)		Provided February 11, 2025
Projected product gross margin GAAP to non-GAAP reconciliation:
GAAP projected product gross margin		77.0% - 78.0%
Acquisition-related expenses		~ 8.0%
Non-GAAP projected product gross margin		85.0% - 86.0%
Projected operating income GAAP to non-GAAP reconciliation:
GAAP projected operating income		$10,200 - $10,700
Acquisition-related and restructuring expenses		~ 2,500
Non-GAAP projected operating income		$12,700 - $13,200
Projected effective tax rate GAAP to non-GAAP reconciliation:
GAAP projected effective tax rate		~ 20%
Income tax effect of above non-GAAP adjustments, and discrete and related tax adjustments		(~ 1%)
Non-GAAP projected effective tax rate		~ 19%
Projected diluted EPS GAAP to non-GAAP reconciliation:
GAAP projected diluted EPS		$5.95 - $6.35
Acquisition-related and restructuring expenses, and discrete and related tax adjustments		~ 1.75
Non-GAAP projected diluted EPS		$7.70 - $8.10

________________________________
(1)		Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and in-process research and development, transfers of intangible assets from a foreign subsidiary to Ireland and the United States, and legal entity restructurings.

GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
		December 31,
(in millions)		2024			2023
Assets
Cash, cash equivalents and marketable debt securities		$	9,991		$	8,428
Accounts receivable, net			4,420			4,660
Inventories			3,589			3,366
Property, plant and equipment, net			5,414			5,317
Intangible assets, net			19,948			26,454
Goodwill			8,314			8,314
Other assets			7,319			5,586
Total assets		$	58,995		$	62,125
Liabilities and Stockholders’ Equity
Current liabilities		$	12,004		$	11,280
Long-term liabilities			27,744			28,096
Stockholders’ equity(1)			19,246			22,749
Total liabilities and stockholders’ equity		$	58,995		$	62,125

________________________________
(1)		As of December 31, 2024 and 2023, there were 1,246 shares of common stock issued and outstanding.

GILEAD SCIENCES, INC. SELECTED CASH FLOW INFORMATION (unaudited)
		Three Months Ended								Twelve Months Ended
		December 31,								December 31,
(in millions)			2024				2023				2024				2023
Net cash provided by operating activities		$	2,975			$	2,168			$	10,828			$	8,006
Net cash used in investing activities			(225	)			(726	)			(3,449	)			(2,265	)
Net cash used in financing activities			2,260				(1,100	)			(3,433	)			(5,125	)
Effect of exchange rate changes on cash and cash equivalents			(55	)			37				(40	)			57
Net change in cash and cash equivalents			4,954				380				3,906				673
Cash and cash equivalents at beginning of period			5,037				5,705				6,085				5,412
Cash and cash equivalents at end of period		$	9,991			$	6,085			$	9,991			$	6,085

		Three Months Ended								Twelve Months Ended
		December 31,								December 31,
(in millions)			2024				2023				2024				2023
Net cash provided by operating activities		$	2,975			$	2,168			$	10,828			$	8,006
Capital expenditures			(147	)			(214	)			(523	)			(585	)
Free cash flow(1)		$	2,828			$	1,954			$	10,305			$	7,421

________________________________
(1)		Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above.

GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited)
		Three Months Ended						Twelve Months Ended
		December 31,						December 31,
(in millions)		2024			2023			2024			2023
HIV
Biktarvy – U.S.		$	3,129		$	2,588		$	10,855		$	9,692
Biktarvy – Europe			400			333			1,509			1,253
Biktarvy – Rest of World			246			188			1,060			905
			3,774			3,109			13,423			11,850
Descovy – U.S.			563			457			1,902			1,771
Descovy – Europe			25			25			100			100
Descovy – Rest of World			28			28			110			114
			616			509			2,113			1,985
Genvoya – U.S.			410			447			1,498			1,752
Genvoya – Europe			42			48			180			205
Genvoya – Rest of World			18			22			84			103
			470			517			1,762			2,060
Odefsey – U.S.			252			258			957			1,012
Odefsey – Europe			74			71			290			294
Odefsey – Rest of World			11			11			41			44
			336			340			1,288			1,350
Symtuza - Revenue share(1) – U.S.			112			104			450			382
Symtuza - Revenue share(1) – Europe			30			32			130			133
Symtuza - Revenue share(1) – Rest of World			3			3			12			13
			144			139			592			529
Other HIV(2) – U.S.			67			46			257			238
Other HIV(2) – Europe			33			25			129			116
Other HIV(2) – Rest of World			11			9			48			47
			111			79			434			401
Total HIV – U.S.			4,532			3,899			15,918			14,848
Total HIV – Europe			603			533			2,339			2,102
Total HIV – Rest of World			317			261			1,355			1,226
			5,452			4,693			19,612			18,175
Liver Disease
Sofosbuvir / Velpatasvir(3) – U.S.			185			216			922			859
Sofosbuvir / Velpatasvir(3) – Europe			69			74			299			323
Sofosbuvir / Velpatasvir(3) – Rest of World			75			89			374			355
			330			378			1,596			1,537
Vemlidy – U.S.			148			115			486			410
Vemlidy – Europe			11			10			44			38
Vemlidy – Rest of World			100			92			428			414
			260			217			959			862
Other Liver Disease(4) – U.S.			58			39			192			152
Other Liver Disease(4) – Europe			54			38			202			150
Other Liver Disease(4) – Rest of World			18			19			73			83
			130			96			467			385
Total Liver Disease – U.S.			391			370			1,601			1,421
Total Liver Disease – Europe			134			121			545			511
Total Liver Disease – Rest of World			194			200			876			852
			719			691			3,021			2,784
Veklury
Veklury – U.S.			108			364			892			972
Veklury – Europe			80			181			284			408
Veklury – Rest of World			150			175			623			805
			337			720			1,799			2,184

GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited)
		Three Months Ended						Twelve Months Ended
		December 31,						December 31,
(in millions)		2024			2023			2024			2023
Oncology
Cell Therapy
Tecartus – U.S.			53			66			234			245
Tecartus – Europe			36			27			138			110
Tecartus – Rest of World			10			5			31			15
			98			98			403			370
Yescarta – U.S.			161			187			662			811
Yescarta – Europe			156			140			666			547
Yescarta – Rest of World			72			42			242			140
			390			368			1,570			1,498
Total Cell Therapy – U.S.			213			253			896			1,055
Total Cell Therapy – Europe			193			167			804			658
Total Cell Therapy – Rest of World			82			46			274			156
			488			466			1,973			1,869
Trodelvy
Trodelvy – U.S.			247			226			902			777
Trodelvy – Europe			77			48			294			217
Trodelvy – Rest of World			31			24			119			68
			355			299			1,315			1,063
Total Oncology – U.S.			461			479			1,798			1,833
Total Oncology – Europe			269			216			1,098			875
Total Oncology – Rest of World			113			70			393			224
			843			765			3,289			2,932
Other
AmBisome – U.S.			7			4			44			43
AmBisome – Europe			66			68			276			260
AmBisome – Rest of World			36			39			212			189
			109			111			533			492
Other(5) – U.S.			51			64			255			261
Other(5) – Europe			8			9			34			40
Other(5) – Rest of World			16			17			68			66
			76			90			356			367
Total Other – U.S.			59			68			299			304
Total Other – Europe			74			77			310			301
Total Other – Rest of World			52			56			280			255
			184			201			889			859
Total product sales – U.S.			5,550			5,180			20,508			19,377
Total product sales – Europe			1,160			1,128			4,576			4,197
Total product sales – Rest of World			826			762			3,526			3,361
		$	7,536		$	7,070		$	28,610		$	26,934

________________________________
(1)		Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.
(2)		Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.
(3)		Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).
(4)		Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi, Sovaldi, Viread and Vosevi.
(5)		Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211220195/en/

Investors:

Jacquie Ross, CFA

investor_relations@gilead.com

Media:

Ashleigh Koss

public_affairs@gilead.com

Source: Gilead Sciences, Inc.

FAQ

What was Gilead's (GILD) total revenue growth in 2024?

Gilead's total revenue increased 6% to $28.8 billion in 2024 compared to 2023.

How much did GILD's Biktarvy sales grow in 2024?

Biktarvy sales increased 13% to $13.4 billion in 2024 compared to 2023.

What is GILD's revenue guidance for 2025?

Gilead expects total product sales between $28.2-28.6 billion for 2025.

How much did GILD's Veklury sales decline in 2024?

Veklury sales decreased 18% to $1.8 billion in 2024 compared to 2023.

What was GILD's cash position at the end of 2024?

Gilead had $10.0 billion in cash, cash equivalents and marketable debt securities as of December 31, 2024.